Universe Pharmaceuticals INC (UPC) AI Stock Analysis

Universe Pharmaceuticals INC is a pharmaceutical enterprise based in Ji'An, China, specializing in the production, marketing, distribution, and sale of traditional Chinese medicine derivative products. Established in 2019 and operating as a subsidiary of Sununion Holding Group Limited, the company develops treatments for chronic conditions common among elderly populations, as well as cold and flu medications. It also distributes third-party biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its customer base includes pharmaceutical companies, hospitals, clinics, and drugstore chains across China.

Revenue declined over consecutive years, falling from $48.0M in FY2021 to $40.1M in FY2022, $32.3M in FY2023, $23.0M in FY2024, and $17.9M in FY2025, reflecting a 5-year revenue CAGR of -10.3%. Operating margin deteriorated from 28.3% in FY2021 to -16.3% in FY2025. Net income was $11.3M in FY2021 before turning negative, with net income of -$8.7M in FY2022, -$6.2M in FY2023, -$8.7M in FY2024, and -$3.7M in FY2025. Over the trailing twelve months, revenue reached $17.7M with an operating margin of -16.6% and EPS of -$1.38. For the quarter ended June 30, 2026, revenue fell 1.3% and earnings fell 82.0% year-over-year.

As of June 30, 2026, Universe Pharmaceuticals held $29.0M in cash and short-term investments and $9.6M in total debt, yielding net cash of $19.5M. Total assets stood at $71.5M against shareholders' equity of $55.6M, with a debt-to-equity ratio of 0.17 and a current ratio of 4.05. In FY2025, operating cash flow was -$5.1M and free cash flow was -$5.4M, with capital expenditures of $347,187. Over five years, the share count increased by 10528.3%.

Universe Pharmaceuticals traded at $3.93 on October 16, 2026, with a market capitalization of $19.7M and an enterprise value of $4.1M. The stock trades at a price-to-sales multiple of 1.1x and an EV/EBITDA of 0.3x, both below the median of its US-listed Healthcare peers, which stand at 4.1x and 12.0x, respectively. It also trades at a price-to-book ratio of 0.4x. Over the past year, the shares fell 27.9%, while the S&P 500 gained 16.8%. Over five years, the stock fell 99.7% compared to an 83.0% gain for the benchmark index.

Universe Pharmaceuticals recorded 0 EPS beats over the last 4 quarters. The company has no consensus analyst ratings, price targets, or published forward earnings estimates. Insiders hold 88.8% of outstanding shares, while institutional ownership stands at 2.2%. Short interest represents 0.9% of the float. The stock exhibits elevated price fluctuation relative to the broader market, indicated by a beta of 1.68, and closed at $3.93 on October 16, 2026, which is 1.4% above its 200-day moving average.

This page is an AI-written research summary of Universe Pharmaceuticals INC (UPC). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: UPC income statement, UPC balance sheet, UPC key metrics, UPC chart. See the UPC stock overview for the latest quote and news.